David Liew

@drdavidliew

Rheumatologist and clinical pharmacologist, world traveller pretences, and even sometimes journal podcast host. All opinions my own

Melbourne, Australia

linktr.ee/drdavidliew

Joined September 2016

Pinned
David Liew
@drdavidliew
Jun 23, 2025
Why does it seem like PMR patients get stuck in situations we would never tolerate for other patients? @drceowen and I call out many reasons. PMR is killing them softly, and will continue to do so if collectively we neglect it. now out @TheLancetRheum: thelancet.com/journals/lanrh…
David Liew
@drdavidliew
Jun 7
Let's talk RA-BRIDGE/RA-BRANCH (the 'new ORAL Surveillance'): baricitinib vs TNFi RCTs in RA + 1 VTE RF Big news was secondary endpoints: MACE (HR 1.06), malignancy (HR 1.27), not sig The key: how similar is study population to ORAL Surveillance? 1/4 LB0009 #EULAR2026 @RheumNow
David Liew
@drdavidliew
Jun 2
Big #EULAR2026, I'm sad to be missing esp a massive late breaking session: baricitinib postmarketing is here! RA-BRIDGE/RA-BRANCH (RA + 1 VTE RF) RCT: baricitinib vs TNFi From the abstract: no MACE/cancer signal 😲 what now for JAKi safety, ORAL Surveillance? LB0009 @RheumNow
David Liew
@drdavidliew
Jun 7
Which biologic works best in psoriasis? BE-BOLD at #EULAR2026 is the first IL-17A/F vs IL-23p19 head-to-head (bim vs ris), and it's in PsA. but so many H2H in psoriasis! I wanted to compile them, so I asked ChatGPT to put a table together, and it seems to check out: @RheumNow
Dr. John Cush
@RheumNow
Jun 6
DAY 4 Recap: EULAR 2026 Highlights x.com/i/broadcasts/1…
REPLAY
Dr. John Cush
@RheumNow
DAY 4 Recap: EULAR 2026 Highlights
David Liew
@drdavidliew
Jun 2
Big #EULAR2026, I'm sad to be missing esp a massive late breaking session: baricitinib postmarketing is here! RA-BRIDGE/RA-BRANCH (RA + 1 VTE RF) RCT: baricitinib vs TNFi From the abstract: no MACE/cancer signal 😲 what now for JAKi safety, ORAL Surveillance? LB0009 @RheumNow
David Liew
@drdavidliew
Dec 14, 2025
Nice article from Ronald van Vollenhoven in @eular_org EULAR Rheumatology Open, summarising the issues with lupus endpoint science: ero.eular.org/article/S3050-… For non-lupologist rheumatologists like me, an excellent primer on SLE outcomes (but always happy to defer to @alberta_hoi)
Lupus trials and tribulations: are outcome measures the problem?
From ero.eular.org